Status:
RECRUITING
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Lead Sponsor:
Eli Lilly and Company
Conditions:
Lymphoma, Non-Hodgkin
Leukemia, Lymphocytic, Chronic, B-Cell
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to find out more about the long-term safety of pirtobrutinib in participants with previously treated types of blood cancer. Participants must have chronic lymphocytic leuk...
Eligibility Criteria
Inclusion
- Currently enrolled and active in the originator study, JZNJ. A participant is considered active in the study if they are receiving study intervention
- Agree to comply with contraception requirements. Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
Exclusion
- Are pregnant, or intend to become pregnant during the study, or within 30 days of last dose of study treatment or to breastfeed during the study or within 1 week of the last dose of study treatment
Key Trial Info
Start Date :
August 7 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2030
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT07162181
Start Date
August 7 2025
End Date
May 1 2030
Last Update
December 4 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer hospital
Beijing, China, 100142
2
Sun Yat-sen University Cancer Center
Guangzhou, China, 510060
3
Harbin Medical University Cancer Hospital
Harbin, China, 150081
4
Shanghai East Hospital
Shanghai, China, 200123